Novavax Inc (NAS:NVAX)
$ 17.47 2.44 (16.23%) Market Cap: 2.57 Bil Enterprise Value: 1.99 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Novavax, Inc. - Special Call Transcript

Feb 28, 2019 / 01:00PM GMT
Release Date Price: $14.1 (-66.90%)
Operator

Good day, ladies and gentlemen, and welcome to the Novavax Prepare Trial Topline Results Call. (Operator Instructions) And as a reminder, today's conference call is being recorded. I'd now like to turn the conference over to Erika Trahan, Senior Manager of Investor and Public Relations. Please go ahead.

Erika S. Trahan
Novavax, Inc. - Senior Manager of Investor & Public Relations

Thank you, operator. Good morning. I would like to thank everyone for joining today's call to discuss the Prepare Trial Topline Results. A press release is currently available on our website at novavax.com and an audio archive of this conference call will be available on our website later today.

Joining me on today's call is Stan Erck; President and CEO of Novavax; and Dr. Gregory Glenn, President of Research & Development. Dr. Louis Fries, Chief Medical Officer; John Trizzino, Chief Business Officer and Chief Financial Officer; and Amy Fix, Senior Vice President of Regulatory Affairs will also be available for the Q&A portion of the call.

Before we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot